{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T13:44:54Z","timestamp":1774014294066,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd008814","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T00:00:00Z","timestamp":1505260800000}}],"reference-count":108,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008814.pub2","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T07:24:48Z","timestamp":1505287488000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis"],"prefix":"10.1002","volume":"2017","author":[{"given":"Jeremy","family":"Franklin","sequence":"first","affiliation":[{"name":"University Hospital of Cologne; Institute of Medical Statistics, Informatics and Epidemiology; Kerpener Str. 62 Cologne Germany 50937"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis A.","family":"Eichenauer","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Department I of Internal Medicine, Center of Integrated Oncology K\u00f6ln Bonn; Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Becker","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Institute of Medical Statistics, Informatics and Epidemiology; Kerpener Str. 62 Cologne Germany 50937"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"University Hospital of Cologne; Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,9,13]]},"reference":[{"issue":"18","key":"10.1002\/14651858.CD008814.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1200\/JCO.2002.12.007","article-title":"Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy","volume":"20","author":"Nachman","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"26","key":"10.1002\/14651858.CD008814.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1200\/JCO.2011.41.1819","article-title":"Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherpay for children with Hodgkin's lymphoma - a report from the Children's Oncology Group","volume":"30","author":"Wolden","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD008814.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD008814.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa022628","article-title":"Involved-field radiotherapy for advanced Hodgkin's lymphoma","volume":"348","author":"Aleman","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"19","key":"10.1002\/14651858.CD008814.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease","volume":"357","author":"Ferm\u00e9","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"Suppl. 5","key":"10.1002\/14651858.CD008814.pub2-BIB0006|cit6","first-page":"27","article-title":"Results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL)","volume":"92","author":"Thomas","year":"2007","journal-title":"Haematologica"},{"issue":"Suppl. 5","key":"10.1002\/14651858.CD008814.pub2-BIB0007|cit7","first-page":"27","article-title":"Results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL)","volume":"92","author":"Thomas","year":"2007","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0008|cit8","unstructured":"Gerhartz HH Schwenke H Bazarbashi S Thiel E Blau W Huhn D Randomized comparison of COPP\/ABVD versus dose- and time-escalated COPP\/ABVD with GM-CSF support for advanced Hodgkin's disease ASCO Annual Meeting Proceedings 1997"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0009|cit9","unstructured":"Gerhartz HH Schwenke H Bazarbashi S Thiel E Blau W Huhn D Randomized comparison of COPP\/ABVD versus dose- and time-escalated COPP\/ABVD with GM-CSF support for advanced Hodgkin's disease Oncology 1999 31"},{"issue":"7","key":"10.1002\/14651858.CD008814.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"27","key":"10.1002\/14651858.CD008814.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD008814.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/oxfordjournals.annonc.a059357","article-title":"Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease","volume":"6","author":"Diehl","year":"1995","journal-title":"Annals of Oncology"},{"issue":"19","key":"10.1002\/14651858.CD008814.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","article-title":"Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin\u2019s lymphoma: Results of the HD8 trial of the German Hodgkin\u2019s Lymphoma Study Group","volume":"21","author":"Engert","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD008814.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease","volume":"348","author":"Diehl","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008814.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi trial","volume":"27","author":"Federico","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"32","key":"10.1002\/14651858.CD008814.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1200\/JCO.2010.30.9799","article-title":"Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP\/EBV\/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi","volume":"29","author":"Chisesi","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD008814.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD008814.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/00043426-200606000-00008","article-title":"POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with stages I, IIA, IIIA1 Hodgkin disease: a report from the Children's Oncology Group","volume":"28","author":"Kung","year":"2006","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"6","key":"10.1002\/14651858.CD008814.pub2-BIB0020|cit20","first-page":"4045","article-title":"Intermediate stage Hodgkin's disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy","volume":"24","author":"Anselmo","year":"2004","journal-title":"Anticancer Research"},{"issue":"1","key":"10.1002\/14651858.CD008814.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1200\/JCO.2004.01.021","article-title":"Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?","volume":"22","author":"Laskar","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"36","key":"10.1002\/14651858.CD008814.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1200\/JCO.2005.03.2151","article-title":"Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 trial (ISRCTN97144519)","volume":"23","author":"Johnson","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"36","key":"10.1002\/14651858.CD008814.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1200\/JCO.2005.03.2151","article-title":"Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 trial (ISRCTN97144519)","volume":"23","author":"Johnson","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"32","key":"10.1002\/14651858.CD008814.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2009.23.3239","article-title":"Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group study ISRCTN 64141244","volume":"27","author":"Hoskin","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD008814.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdu189","article-title":"ABVD (8 cycles) versus BEACOPP (4 escalated cycles \u22654 baseline): final results in stage III\u2013IV low-risk Hodgkin lymphoma (IPS 0\u20132) of the LYSA H34 randomized trial","volume":"25","author":"Mounier","year":"2014","journal-title":"Annals of Oncology"},{"issue":"9","key":"10.1002\/14651858.CD008814.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial","volume":"30","author":"Tresckow","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"10.1002\/14651858.CD008814.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin's disease","volume":"21","author":"Aleman","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD008814.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/annonc\/mdh273","article-title":"Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group","volume":"15","author":"Behringer","year":"2004","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD008814.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3816\/CLM.2007.n.028","article-title":"The effect of radiologic imaging studies on the risk of secondary malignancy development in patients with Hodgkin lypmhoma","volume":"7","author":"Beyan","year":"2007","journal-title":"Clinical Lymphoma and Myeloma"},{"issue":"12","key":"10.1002\/14651858.CD008814.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM199603213341201","article-title":"Breast cancer and other second neoplasms after childhood Hodgkin's disesase","volume":"334","author":"Bhatia","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008814.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0360-3016(96)00489-0","article-title":"Gastrointestinal cancer after treatment of Hodgkin's disease","volume":"37","author":"Birdwell","year":"1997","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"1","key":"10.1002\/14651858.CD008814.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0360-3016(94)90222-4","article-title":"Second solid tumors and leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution","volume":"29","author":"Biti","year":"1994","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00004032-198810000-00003","article-title":"Carcinogenesis - a synopsis of human experience with external exposure in medicine","volume":"55","author":"Boice","year":"1988","journal-title":"Health Physics"},{"issue":"10","key":"10.1002\/14651858.CD008814.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/jnci\/87.10.732","article-title":"Incidence of second cancers in patients treated for Hodgkin's disease","volume":"87","author":"Boivin","year":"1995","journal-title":"Journal of the National Cancer Institute"},{"issue":"9","key":"10.1002\/14651858.CD008814.pub2-BIB0035|cit35","first-page":"812","article-title":"The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher after combined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study","volume":"83","author":"Brusamolino","year":"1998","journal-title":"Haematologica"},{"issue":"24","key":"10.1002\/14651858.CD008814.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1056\/NEJMc0906731","article-title":"Long-term follow-up of survival in Hodgkin's lymphoma","volume":"361","author":"Canellos","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008814.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"Journal of the Royal Statistical Society Series B"},{"issue":"26","key":"10.1002\/14651858.CD008814.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","article-title":"Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller rafiation volumes","volume":"27","author":"Bruin","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0039|cit39","article-title":"Hodgkin's disease","volume-title":"Cancer: Principles and Practice of Oncology","author":"Diehl","year":"2000"},{"issue":"1","key":"10.1002\/14651858.CD008814.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1365-2141.2002.03564.x","article-title":"Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation","volume":"118","author":"Delwail","year":"2002","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD008814.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood.V84.4.1209.1209","article-title":"Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen?","volume":"84","author":"Dietrich","year":"1994","journal-title":"Blood"},{"issue":"16","key":"10.1002\/14651858.CD008814.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2002.09.038","article-title":"Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years","volume":"20","author":"Dores","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJM198812293192601","article-title":"Effects of adjuvant Tamoxifen and of cytotoxic therapy on mortality in early breast cancer","volume":"319","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1988","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1-15, 71-85","DOI":"10.1016\/0140-6736(92)90997-H","article-title":"Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy","volume":"339","author":"Early Breast Cancer Triallists' Collaborative Group","year":"1992","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD008814.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2013-07-512657","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"123","author":"Eichenauer","year":"2014","journal-title":"Blood"},{"issue":"27","key":"10.1002\/14651858.CD008814.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"9828","key":"10.1002\/14651858.CD008814.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD008814.pub2-BIB0048|cit48","first-page":"636","article-title":"The risk of non-Hodgkin's lymphoma after Hodgkin's disease, with special reference to splenic treatment","volume":"83","author":"Enrici","year":"1998","journal-title":"Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD008814.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.1993.11.2.255","article-title":"Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time and age","volume":"11","author":"Foss-Abrahamsen","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD008814.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/annonc\/mdf289","article-title":"Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time","volume":"13","author":"Foss-Abrahamsen","year":"2002","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1002\/14651858.CD008814.pub2-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003187.pub2","article-title":"Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk","author":"Franklin","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD008814.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/annonc\/mdl302","article-title":"Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials","volume":"17","author":"Franklin","year":"2006","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0053|cit53","unstructured":"Franklin J Hozo I Pluetschow A Djulbegovic B Competing risks with time-to-event outcomes in an individual patient data meta-analysis Deutsche Gesellschaft f\u00fcr Medizinische Informatik, Biometrie und Epidemiologie e.V. (gmds). 51. Jahrestagung der Deutschen Gesellschaft f\u00fcr Medizinische Informatik, Biometrie und Epidemiologie D\u00fcsseldorf, K\u00f6ln German Medical Science 2006"},{"issue":"7650","key":"10.1002\/14651858.CD008814.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD008814.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jnci\/85.1.25","article-title":"Breast cancer after treatment of Hodgkin's disease","volume":"85","author":"Hancock","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/3.suppl_4.S117","article-title":"Second cancer after the treatment of Hodgkin's disease: a report from the International Database on Hodgkin's disease","volume":"3 Suppl 4","author":"Henry-Amar","year":"1992","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD008814.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0889-8588(18)30246-6","article-title":"Acute leukemia after the treatment of Hodgkin's disease","volume":"7","author":"Henry-Amar","year":"1993","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/annonc\/7.suppl_4.S115","article-title":"Late complications after Hodgkin's disease","volume":"7 Suppl 4","author":"Henry-Amar","year":"1996","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD008814.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3324\/haematol.2009.015644","article-title":"Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review","volume":"95","author":"Herbst","year":"2010","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0061|cit61","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0)","author":"Higgins","year":"2011"},{"issue":"12","key":"10.1002\/14651858.CD008814.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma","volume":"25","author":"Hodgson","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/bmt.2012.282","article-title":"EBMT statistical guidelines. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation","volume":"48","author":"Iacobelli","year":"2013","journal-title":"Bone Marrow Transplantation"},{"issue":"18","key":"10.1002\/14651858.CD008814.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1200\/JCO.2003.07.160","article-title":"Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group","volume":"21","author":"Josting","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJM199001043220102","article-title":"Leukemia following Hodgkin's disease","volume":"322","author":"Kaldor","year":"1990","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ijc.2910520502","article-title":"Lung cancer following Hodgkin's disease: a case-control study","volume":"52","author":"Kaldor","year":"1992","journal-title":"International Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD008814.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/JCO.2012.44.5791","article-title":"Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials","volume":"31","author":"Koontz","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD008814.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ijrobp.2010.10.069","article-title":"Declining use of radiotherapy in stage I and II hodgkin's disease and its effect on survival and secondary malignancies","volume":"82","author":"Koshy","year":"2012","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"issue":"10","key":"10.1002\/14651858.CD008814.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3324\/haematol.11034","article-title":"Therapy-related leukemia and myelodysplasia: susceptibility and incidence","volume":"92","author":"Leone","year":"2007","journal-title":"Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD008814.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1200\/JCO.1998.16.3.818","article-title":"Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease","volume":"16","author":"Loeffler","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD008814.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1182\/blood.V87.9.3625.bloodjournal8793625","article-title":"Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome","volume":"87","author":"Mauch","year":"1996","journal-title":"Blood"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0072|cit72","volume-title":"Hodgkin's Disease","author":"Mauch","year":"1999"},{"issue":"3","key":"10.1002\/14651858.CD008814.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1524-4741.2010.00904.x","article-title":"Breast cancer following Hodgkin's disease: the experience of the University of Florence","volume":"16","author":"Meattini","year":"2010","journal-title":"Breast Journal"},{"issue":"5","key":"10.1002\/14651858.CD008814.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin\u2019s lymphoma","volume":"366","author":"Meyer","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008814.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD008814.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdu189","article-title":"ABVD (8 cycles) versus BEACOPP (4 escalated cycles \u22654baseline): final results in stage III\u2013IV low-risk Hodgkinlymphoma (IPS 0\u20132) of the LYSA H34 randomized trial","volume":"25","author":"Mounier","year":"2014","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0077|cit77","first-page":"61","article-title":"The epidemiology of Hodgkin's disease","volume-title":"Hodgkin's Disease","author":"Mueller","year":"1999"},{"issue":"6","key":"10.1002\/14651858.CD008814.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin's disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors","volume":"100","author":"Ng","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD008814.pub2-BIB0079|cit79","first-page":"27","article-title":"Late complications of therapy of Hodgkin's disease: Prevention and management","volume":"3","author":"Ng","year":"2004","journal-title":"Current Hematology Reports"},{"issue":"8550","key":"10.1002\/14651858.CD008814.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(87)92744-9","article-title":"Risk of therapy-related leukemia and preleukemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy","volume":"2","author":"Pedersen-Bjergaard","year":"1987","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/sim.4780120803","article-title":"Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?","volume":"12","author":"Pepe","year":"1993","journal-title":"Statistics in Medicine"},{"issue":"12","key":"10.1002\/14651858.CD008814.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0083|cit83","unstructured":"The Nordic Cochrane Centre Review Manager (RevMan) 2012"},{"issue":"2","key":"10.1002\/14651858.CD008814.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/oxfordjournals.annonc.a058414","article-title":"Hodgkin's disease: study of treatment intensities and incidences of second malignancies","volume":"4","author":"Rodriguez","year":"1993","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD008814.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1200\/JCO.2001.19.7.2026","article-title":"Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin'sLymphoma Study Group: incidence, treatment, and prognosis","volume":"19","author":"Rueffer","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD008814.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1093\/annonc\/mds110","article-title":"Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma","volume":"23","author":"Sasse","year":"2012","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD008814.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/annonc\/mdq408","article-title":"Impact of first- and second.line treatment for Hodgkin's lymphoma on the incidence of AML\/MDS and NHL - experience of the German Hodgkin's Lymphoma Study Group analysed by a parametric model of carcinogenesis","volume":"22","author":"Scholz","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/1097-0142(19900301)65:5<1155::AID-CNCR2820650521>3.0.CO;2-7","article-title":"A Meta-analysis of stages I and II Hodgkin's disease","volume":"65","author":"Shore","year":"1990","journal-title":"Cancer"},{"issue":"10","key":"10.1002\/14651858.CD008814.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(13)70341-3","article-title":"Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis","volume":"14","author":"Skoetz","year":"2013","journal-title":"Lancet Oncology"},{"issue":"3","key":"10.1002\/14651858.CD008814.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.1998.16.3.830","article-title":"Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients","volume":"16","author":"Specht","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/bmj.304.6835.1137","article-title":"Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation","volume":"304","author":"Swerdlow","year":"1992","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2000.18.3.498","article-title":"Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment","volume":"18","author":"Swerdlow","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD008814.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1200\/JCO.2001.19.6.1610","article-title":"Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment","volume":"19","author":"Swerdlow","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"31","key":"10.1002\/14651858.CD008814.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2011.34.8268","article-title":"Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study","volume":"29","author":"Swerdlow","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD008814.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2011.38.8835","article-title":"Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin\u2019s lymphoma in England and Wales: a national cohort study","volume":"30","author":"Swerdlow","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/sim.711","article-title":"Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches","volume":"20","author":"Tai","year":"2001","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","article-title":"Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease","volume":"94","author":"Travis","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"issue":"4","key":"10.1002\/14651858.CD008814.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin's disease","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM198801143180203","article-title":"Risk of second cancers after treatment for Hodgkin's disease","volume":"318","author":"Tucker","year":"1988","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD008814.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0889-8588(18)30247-8","article-title":"Solid second cancers following Hodgkin's disease","volume":"7","author":"Tucker","year":"1993","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"10.1002\/14651858.CD008814.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1200\/JCO.1994.12.2.312","article-title":"Second cancer risk following Hodgkin's disease: a 20-year follow-up study","volume":"12","author":"Leeuwen","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD008814.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/JCO.1994.12.5.1063","article-title":"Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkalating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage","volume":"12","author":"Leeuwen","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"20","key":"10.1002\/14651858.CD008814.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jnci\/87.20.1530","article-title":"Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease","volume":"87","author":"Leeuwen","year":"1995","journal-title":"Journal of the National Cancer Institute"},{"issue":"13","key":"10.1002\/14651858.CD008814.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/jnci\/95.13.971","article-title":"Roles of radiotherapy dose, chemotherapy, and hormonal status in breast cancer following Hodgkin's disease","volume":"95","author":"Leeuwen","year":"2003","journal-title":"Journal of the National Cancer Institute"},{"issue":"9","key":"10.1002\/14651858.CD008814.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial","volume":"30","author":"Tresckow","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"26","key":"10.1002\/14651858.CD008814.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1200\/JCO.2011.41.1819","article-title":"Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherpay for children with Hodgkin's lymphoma - a report from the Children's Oncology Group","volume":"30","author":"Wolden","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"10.1002\/14651858.CD008814.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1002\/cncr.28194","article-title":"Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors","volume":"119","author":"Xavier","year":"2013","journal-title":"Cancer"},{"issue":"11","key":"10.1002\/14651858.CD008814.pub2-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008814","article-title":"Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival","author":"Franklin","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD008814.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T22:27:00Z","timestamp":1719440820000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008814.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,13]]},"references-count":108,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008814.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,13]]}}}